Saccharomyces boulardii 관련 Antibiotic-Associated Diarrhea (AAD)
AMultiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
A
결론
Multiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.
Key Study Findings
Observational Study
n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None
vs: None
Outcome: Probiotic prescribing habits of Italian PCPs
효과: L. rhamnosus GG used by 91.8%
None
대상 집단: Italian primary care pediatricians
Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None
vs: None
Outcome: None
효과: None
None
대상 집단: Pediatric population
Review
Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping …
Dose: None
vs: None
Outcome: None
효과: None
None
대상 집단: scoping review of intestinal dysbiosis definition, symptoms, and probiotic adjuvant therapy in adults and children
Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None
vs: None
Outcome: Clinical guideline recommendations for pediatric GI
효과: None
None
대상 집단: Pediatric patients with GI disorders
Review
Clostridioides difficile Infections: Prevention and Treatment Strategies.
Dose: None
vs: None
Outcome: C. difficile infection treatment outcomes
효과: None
None
대상 집단: Patients with C. difficile infection
Randomized Controlled Trial
n=47
1 weeks
[A prospective randomized controlled study on probiotics for the prevention of antibiotic-associated diarrhea in infants …
Dose: None
vs: Control
Outcome: Gut microbiota composition
효과: None
P<0.017
대상 집단: Children
Key Statistics
25
연구
5000
참여자
↑
Positive
A
등급
Referenced Papers
Probiotics and antimicrobial …
2025
26 인용
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Review
Journal of gastroenterology …
2025
10 인용
Antibiotics (Basel, Switzerland)
2025
Boletin medico del …
2025
Open forum infectious …
2024
7 인용
Zhongguo dang dai …
2024
5 인용
Advances in experimental …
2024
2 인용
Therapeutic advances in …
2023
97 인용
Overview of systematic reviews of probiotics in the prevention and treatment of antibiotic-associated diarrhea in children.
Systematic Review
Frontiers in pharmacology
2023
20 인용
Cureus
2023
19 인용
Cureus
2023
5 인용
The Journal of …
2023
1 인용
Archivos argentinos de …
2022
23 인용
Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections.
Review
World journal of …
2019
92 인용
Advances in experimental …
2019
17 인용
Frontiers in medicine
2018
450 인용
Choosing an appropriate probiotic product for your patient: An evidence-based practical guide.
Systematic Review
PloS one
2018
205 인용
Pharmacological research
2018
132 인용
World journal of …
2018
52 인용
The American journal …
2018
46 인용
World journal of …
2017
68 인용
Journal of pediatric …
2016
233 인용
Clinical and experimental …
2016
82 인용
Open forum infectious …
2016
58 인용
Digestive diseases (Basel, …
2016
37 인용
The Cochrane database …
2015
233 인용
Antibiotics (Basel, Switzerland)
2015
104 인용
Journal of clinical …
2015
35 인용
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Review
Nutrition in clinical …
2015
31 인용
Nutricion hospitalaria
2015
5 인용
Expert opinion on …
2014
57 인용
MMW Fortschritte der …
2014
14 인용
MMW Fortschritte der …
2014
3 인용
The American journal …
2012
104 인용
Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use.
Other
The American journal …
2012
5 인용
Medycyna wieku rozwojowego
2012
1 인용
Journal of clinical …
2011
432 인용
World journal of …
2010
512 인용
Journal for specialists …
2010
22 인용
Probiotics.
Review
American journal of …
2010
European journal of …
2009
91 인용
Current opinion in …
2009
82 인용
Advances in biochemical …
2008
535 인용
Journal of clinical …
2008
Probiotics.
Review
American family physician
2008
The Journal of …
2007
265 인용
The Cochrane database …
2007
The American journal …
2006
918 인용
Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials.
Meta-Analysis
CMAJ : Canadian …
2006
197 인용
Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea.
Review
Journal of clinical …
2006
112 인용
Medical science monitor …
2006
The American journal …
2001
648 인용
International journal of …
2000
181 인용
Clinical infectious diseases …
1998
346 인용
Anaerobe
1997
40 인용
Gastroenterology
1989
418 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 250-500 mg/day (equivalent to 5-10 billion CFU)
- aadprevention:
- 500 mg/day (start with antibiotic, continue 7 days after)
- cdiffprevention:
- 500 mg twice daily as adjunct to standard therapy
- travelersdiarrhea:
- 250-500 mg/day starting 5 days before travel
상한량: Well-tolerated up to 1,000 mg/day in clinical trials
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Mixed | 279 |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | 1 weeks | Positive | 47 |
| None | 20 weeks | Positive | 564 |
| None | -- | Positive | -- |
권장 복용 시간: Can be taken with or without food; space 2 hours from antifungals
Safety & Side Effects
보고된 부작용
- ⚠ Mild gas and bloating
- ⚠ Rare: fungemia in critically ill patients with central venous catheters
- ⚠ Thirst (yeast may increase water requirements)
- ⚠ Very rare: potential environmental contamination risk in ICU settings
알려진 상호작용
- ● Antifungal medications (may kill S. boulardii, reducing effectiveness)
- ● Monoamine oxidase inhibitors (S. boulardii contains tyramine)
- ● Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)
일일 최대 섭취 허용량: Well-tolerated up to 1,000 mg/day in clinical trials
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does Saccharomyces boulardii help with Antibiotic-Associated Diarrhea (AAD)?
Based on 25 studies with 5,000 participants, there is strong evidence from multiple clinical trials that Saccharomyces boulardii may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is A (Strong Evidence).
How much Saccharomyces boulardii should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Saccharomyces boulardii?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Saccharomyces boulardii and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 25 peer-reviewed studies with 5,000 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: Antibiotic-Associated Diarrhea (AAD)
Saccharomyces boulardii 다른 건강 상태에 대한 근거
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.